Schering AG and Stanford University to cooperate in the field of molecular
imaging
Berlin, November 28, 2006 - Schering AG, Germany (FSE: SCH), majority-owned
by the Bayer Group, and Stanford University, California, USA have started a
joint research program to develop novel molecular imaging agents for the
diagnosis and follow-up of cancer. Specifically, the cooperation will focus
on the identification of novel positron emission tomography (PET) tracers
for tumor imaging.
Under the terms of the agreement, Schering will have the option to assume
exclusive rights for the development and commercialization of such tracers.
"This research cooperation will further strengthen our commitment to the
exciting and fast growing field of molecular imaging and we are proud to
collaborate with Stanford University, one of the leading institutions in
this field," said Xx. Xxxx Xxxxx, Head of Schering AG's Global Business
Unit Diagnostic Imaging. "With our strong network of academic and
industrial partners worldwide, we aim to provide innovative options for the
early and accurate detection and follow-up of cancer diseases - for the
benefit of the patient."
"We are particularly pleased to establish this research collaboration with
Xxxxxxxx AG given their track record as a global pioneer in the development
of diagnostic imaging agents," said Xxxx. Xxx Xxxxxxx from the Xxxxx X.
Xxxxx Center at Stanford University and Director of the Molecular Imaging
Program at Stanford. "This collaboration will help to develop more specific
diagnostics which are needed to identify the most effective treatment for
an individual patient."
Molecular imaging is a novel method of diagnosing early pathological
changes in the body at the molecular level, even before they can be
diagnosed using other imaging procedures. This should allow both the very
early and precise detection and characterization of cancer and other
diseases, e.g. of the central nervous system.
Xxxxxxxx has already established several research collaborations in the
field of molecular imaging. Collaboration partners include Avid
Radiopharmaceuticals Inc., Philadelphia, PA., for the development of novel
diagnostic imaging agents for Alzheimer's disease, as well as the Swiss
Federal Institute of Technology (ETH) Zurich in Switzerland in the field of
PET.
About Schering AG
Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology & Andrology, Oncology,
Diagnostic Imaging as well as Specialized Therapeutics for disabling
diseases. As a global player with innovative products, Schering AG aims for
leading positions in specialized markets worldwide. With in-house R&D and
supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims
to make a recognized contribution to medical progress and strives to
improve the quality of life: making medicine work
It is planned that Schering AG will be renamed Bayer Schering Pharma
Aktiengesellschaft. A corresponding resolution was passed at the
Extraordinary General Meeting of Schering AG on September 13, 2006. Until
the name change has been registered in the commercial register, the company
will continue to operate under the name Schering AG. According to the
resolution of the General Meeting, the Executive Board will not file an
application for registration before December 1, 2006.
About Stanford University
Located between San Francisco and San Xxxx in the heart of Silicon Valley,
Stanford University is recognized as one of the world's leading research
and teaching institutions. Excellence in research in the Schools of
Medicine and Engineering along with the School of Humanities and Sciences
will continue to help drive the field of molecular imaging.
This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.
Your contacts at Schering AG:
Media Relations: Xxxxxx Xxxxxx, T: x00-00-000 124 31,
xxxxxx.xxxxxx@xxxxxxxx.xx
Pharma Communication: Xx. Xxxxxxx Xxxxxx, T: x00-00-000 114 32,
xxxxxxx.xxxxxx@xxxxxxxx.xx
Xxxxxxxx Relations: Xx. Xxxx Xxxxxxxx, T: x00-00-000 150 62,
xxxx.xxxxxxxx@xxxxxxxx.xx
Find additional information at: xxx.xxxxxxxx.xx/xxx
